2026 MCI Breast Cancer Performance Improvement and Quality Improvement Series Evaluation Form - January 6, 2026

Please select one: *

I am in active clinical practice

I am retired

I am a student

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - 0
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 0

As a result of participating in this activity, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Discuss indications of the different ADCs in metastatic breast cancer	Discuss indications of the different ADCs in metastatic breast cancer - 5	Discuss indications of the different ADCs in metastatic breast cancer - 4	Discuss indications of the different ADCs in metastatic breast cancer - 3	Discuss indications of the different ADCs in metastatic breast cancer - 2	Discuss indications of the different ADCs in metastatic breast cancer - 1	Discuss indications of the different ADCs in metastatic breast cancer - 0
Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia).	Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia). - 5	Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia). - 4	Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia). - 3	Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia). - 2	Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia). - 1	Differentiate the toxicity profiles of datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and trastuzumab deruxtecan (T-DXd) (fatigue, nausea, diarrhea, stomatitis, neutropenia). - 0
Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches.	Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches. - 5	Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches. - 4	Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches. - 3	Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches. - 2	Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches. - 1	Discuss evidence-based, proactive strategies to prevent and manage ADC-related adverse events, including antiemetic protocols, diarrhea management algorithms, growth factor use, oral care for stomatitis, and dose-modification approaches. - 0
Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management.	Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management. - 5	Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management. - 4	Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management. - 3	Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management. - 2	Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management. - 1	Discuss clinical and radiographic signs of ADC-associated ILD/pneumonitis and management. - 0

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of what was discussed at this activity what do you intend to do differently? Identify at least two learnings that could be incorporated into your practice *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

You are here

2026 MCI Breast Cancer Performance Improvement and Quality Improvement Series Evaluation Form - January 6, 2026